AzTrials
AzTrials

DepressionSMARTNCT03678194

Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application

A study testing Smartphone Support System in people with Depression and Psychiatric Disorder, run by Centre Hospitalier Charles Perrens, Bordeaux at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Depression, Psychiatric Disorder, Brain Diseases
What is being tested?
Smartphone Support System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteFrance
Study dates
14 Oct 2020to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age between 18 and 65 years;
  • Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;
  • Patients started their antidepressant treatment less than 5 days before inclusion;
  • Patient treated in an outpatient setting;
  • Patient informed of the diagnosis of his disease;
  • Informed patient with written consent.

Who cannot join

  • A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;
  • A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;
  • Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;
  • Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);
  • Non-comprehension of the French language

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

David MISDRAHI, M.D contact

+33(0)556563449

dmisdrahi@ch-perrens.fr

France1 site, 1 recruiting
  • Centre Hospitalier Charles PERRENS

    Bordeaux, 33076

    David MISDRAHI, M.D, 003356563449, dmisdrahi@ch-perrens.fr

    Helen SAVARIEAU, MSc, 003356563556, hsavarieau@ch-perrens.fr

    Recruiting

Other trials in France

About this study

Official title: Treating Depression on a Day-to-day Basis: Development of a Novel Clinical Tool for Physicians Based on a Smartphone Application, the SMART Project (Smartphones and Mood Disorders, an Application for Research and Treatment)

Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.

Read the detailed description

In industrialized countries, depression is the leading cause of disability with a cumulative DALY (disability adjusted life years) that his greater than all the other psychiatric or medical conditions (WHO, 2004). Although the medical treatment is efficient for a large number of patients, two major pitfalls can be highlighted: i). the difficulty to identify and alter risk factors related to therapeutic observance; and ii). the heterogeneous presentation of depression, which may require specific interventions depending on the clinical presentation of the patient.

Ecological Momentary Assessment (EMA; also referred to as the Experience Sampling Method) is a method used to gather and interpret real-time data collected in the contexts of daily life through mobile technologies (Stone 1994). It has been used extensively in the field of psychiatry and specifically in mood disorders and it has been shown to be both feasible for patients with depression (Husky 2010, Swendsen 2012) and effective in identifying determinants of mood fluctuations and medication observance (Myin Germeys 2003, Ebner-Primer 2009, Solhan 2009, Silk 2011, Wichers 2010, Rot 2012, Armey 2015, Wenze 2010, Armey 2015). The restitution of the data to patients also has an important added benefit in terms of prognosis, as patients are better integrated in their own care (Wichers 2011, Kramer 2014).

Although EMA has been shown to offer promising advantages, it has also been limited by the technical solutions used to gather information on daily life experiences. Rather than using research-dedicated devices which represent the majority of existing tools, the development of an application-based solution could revolutionize the field by creating the first effective and widely-diffusable tool to help clinicians better manage depression with the collaboration of their patients. This application would be designed to help patients monitor their symptoms, while providing regular interventions to increase medication.

This is a randomized study in two groups to test and validate an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.

In this multicentric study, 200 patients with a DSM-V diagnosis of depression are recruited.

Participants will be assessed by:

  • Hetero-evaluations: diagnostic (MINI), depressive symptomatology (HDRS), clinical impression (CGI).
  • Auto-evaluations: depressive symptomatology (BDI), medication adherence (MARS), Quality of Life (Q-LES-Q-SF), therapeutic alliance (4PAS).

Two groups will be formed by randomization (100 per groups):

  • Groupe SMART: smartphone (experimental group). This group will performed all clinical evaluations and will download the study application on their smartphone to answer daily questionnaires about symptom severity, medication adherence, during 6 weeks. Participants will be given a smartphone, if the subject does not have one. Clinical visits with psychiatrist will be performed every two weeks, with questionnaires to fill.
  • Groupe TAU: Treatment as Usual (control group). This group will performed all clinical evaluations and have the same follow-up as the intervention group, but without smartphone application.

Expected results Patient benefit: The principle expected benefit for patients concerns their more active participation in their own health care, in the philosophy that the better they understand their disorder and the triggers of symptom expression, the better than can intervene to improve their mental health.

Clinician benefit: It can provide high resolution data of depressive symptoms, therapeutic adherence and symptoms fluctuations on his patients, to better follow the remission or to adjust treatment daily dose.

Being tested
Smartphone Support System
Keywords
Depression, Smartphone, Relapse prevention, Mobile support system, eHealth, Ecological, Randomized, Multicentric
Medical subject headings
Depression, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Smartphone Support SystemDevice

    6 weeks smartphone application with daily evaluations

Study groups in NCT03678194
Study groupRoleWhat they receive
Smartphone applicationExperimentalThis group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up). The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence…
Receives: Device: Smartphone Support System
Standard servicesNo interventionThis group of patients receives conventional treatment only. Clinical evaluations are provided at the same endpoint. Patients still receive standard services for depression.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. A greater clinical response in the active group (smartphone application) comparatively to the comparator group (clinical response was defined as a decline in HDRS-17 score greater than 50%)

    HDRS Hamilton Depressive Rating Scale. Changes in HDRS scores of at least 50% at 8 weeks.

    Measured: Baseline (pre-treatment). 8 weeks post-baseline

Secondary outcomes (3)
  1. Improvement in scores for therapeutic alliance

    Measurement by the 4PAS (4-Point Ordinal Alliance Self-Report)

    Measured: baseline (pre-treatment). 8 weeks post-baseline

  2. Improvement in scores for medication adherence

    Measurement by the MARS (Medical Adherence Rating Scale)

    Measured: 8 weeks after enrollment

  3. Improvement in scores for Quality of Life

    Measurement by the Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form)

    Measured: 8 weeks after enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2018
  2. Study start14 Oct 2020
  3. Primary completion31 Dec 2024
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
200 patients with a DSM-V diagnosis of depression are recruited. Patients are randomly assigned to receive either a 6 weeks smartphone application with daily evaluations, or no application.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03678194
Sponsor's protocol ID
2018 A01465-50
Acronym
SMART
Status last verified
Mar 2026
First submitted
18 Sep 2018
Last updated
16 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Smartphone Support System in people with Depression and Psychiatric Disorder, run by Centre Hospitalier Charles Perrens, Bordeaux at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact David MISDRAHI, M.D (+33(0)556563449, dmisdrahi@ch-perrens.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

A greater clinical response in the active group (smartphone application) comparatively to the comparator group (clinical response was defined as a decline in HDRS-17 score greater than 50%) (time frame: Baseline (pre-treatment). 8 weeks post-baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in